Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

204 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Skin toxicities associated with epidermal growth factor receptor inhibitors.
Li T, Perez-Soler R. Li T, et al. Target Oncol. 2009 Apr;4(2):107-19. doi: 10.1007/s11523-009-0114-0. Epub 2009 May 19. Target Oncol. 2009. PMID: 19452131 Review.
Tumor epidermal growth factor receptor studies in patients with non-small-cell lung cancer or head and neck cancer treated with monoclonal antibody RG 83852.
Perez-Soler R, Donato NJ, Shin DM, Rosenblum MG, Zhang HZ, Tornos C, Brewer H, Chan JC, Lee JS, Hong WK, et al. Perez-Soler R, et al. J Clin Oncol. 1994 Apr;12(4):730-9. doi: 10.1200/JCO.1994.12.4.730. J Clin Oncol. 1994. PMID: 8151316 Clinical Trial.
Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer.
Fossella FV, Lippman SM, Shin DM, Tarassoff P, Calayag-Jung M, Perez-Soler R, Lee JS, Murphy WK, Glisson B, Rivera E, Hong WK. Fossella FV, et al. J Clin Oncol. 1997 Jan;15(1):310-6. doi: 10.1200/JCO.1997.15.1.310. J Clin Oncol. 1997. PMID: 8996158 Clinical Trial.
Topotecan in the treatment of non-small cell lung cancer.
Perez-Soler R. Perez-Soler R. Semin Oncol. 1997 Dec;24(6 Suppl 20):S20-34-S20-41. Semin Oncol. 1997. PMID: 9425959 Review.
Phase I study of paclitaxel administered by ten-day continuous infusion.
Shade RJ, Pisters KM, Huber MH, Fossella F, Perez-Soler R, Shin DM, Kurie J, Glisson B, Lippman S, Lee JS. Shade RJ, et al. Invest New Drugs. 1998-1999;16(3):237-43. doi: 10.1023/a:1006157226693. Invest New Drugs. 1998. PMID: 10360603 Clinical Trial.
Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer.
Shin DM, Donato NJ, Perez-Soler R, Shin HJ, Wu JY, Zhang P, Lawhorn K, Khuri FR, Glisson BS, Myers J, Clayman G, Pfister D, Falcey J, Waksal H, Mendelsohn J, Hong WK. Shin DM, et al. Clin Cancer Res. 2001 May;7(5):1204-13. Clin Cancer Res. 2001. PMID: 11350885 Clinical Trial.
Sensitivity to topoisomerase I inhibitors and cisplatin is associated with epidermal growth factor receptor expression in human cervical squamous carcinoma ME180 sublines.
Ling YH, Donato NJ, Perez-Soler R. Ling YH, et al. Cancer Chemother Pharmacol. 2001 Jun;47(6):473-80. doi: 10.1007/s002800000239. Cancer Chemother Pharmacol. 2001. PMID: 11459199
Tyrosine kinase inhibitors: a clinical perspective.
Goel S, Mani S, Perez-Soler R. Goel S, et al. Curr Oncol Rep. 2002 Jan;4(1):9-19. doi: 10.1007/s11912-002-0043-x. Curr Oncol Rep. 2002. PMID: 11734109 Review.
Chemopreventive therapeutics. Inhalation therapies for lung cancer and bronchial premalignancy.
Haigentz M Jr, Perez-Soler R. Haigentz M Jr, et al. Methods Mol Med. 2003;75:771-80. doi: 10.1385/1-59259-324-0:771. Methods Mol Med. 2003. PMID: 12407778
Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines.
Ling YH, Liebes L, Jiang JD, Holland JF, Elliott PJ, Adams J, Muggia FM, Perez-Soler R. Ling YH, et al. Clin Cancer Res. 2003 Mar;9(3):1145-54. Clin Cancer Res. 2003. PMID: 12631620
204 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback